Journal of Clinical Immunology and Allergy

Novel phytoceutical formula for immunotherapy of HIV/AIDS and cancer

16^th EuroSciCon Conference on Immunology
March 11-12, 2019 | Amsterdam, Netherlands

Pichaet Wiriyachitra

Asian Phytoceuticals Public Company Limited,Thailand

Keynote: J Clin Immunol Allergy

DOI: 10.21767/2471-304X-C1-007

Abstract

Operation BIM (balancing immunity) Research Project was established with the goal of achieving a new dimension of health care utilizing refined extracts from mangosteen, sesame, soy, guava and centella to boost the function of white blood cells. One of the operation BIM formulations, LIV® was found to stimulate body immunity by increasing Th17 conspicuously and Th1 significantly. Clinical studies in HIV infected volunteers confirmed that the formulation conspicuously boosted the CD4 count, reduced the side effects from antiviral drugs and markedly improved the life quality of HIV /AIDS infected patients. The formulation lowered the risk of stage 3 AIDS patients from opportunistic infections by boosting their CD4 number to over 200 cells/mm3 in 1-2 months. Final stage AIDS patients with CD4 less than 10 cells/mm3 were able to raise their CD4 counts to an average of 500 cells/ mm3 in 6 months. A number of patients with opportunistic infections were able to remedy their symptoms within one year and have been living normally with the viral load of less than 20 copies/mm3. In summary, LIV® boosts CD4 count rapidly and can save lives of HIV/AIDS infected patients. A similar formulation, ThPlus®, was used to improve the life quality of cancer patients. Over the past 10 years, numerous cancer patients have recovered from their symptoms and lived normally. In conclusion, the action of the formulation is mediated by increasing Th17 and Th1 which then enhance the activity of cytotoxic T cells in eliminating HIV infected CD4 cells and cancer cells.

Biography

Pichaet Wiriyachitra has completed his PhD from University of Tasmania and Postdoctoral Studies from University of Connecticut and University of Pennsylvania. He served in the Prince of Songkla University and Chiang Mai University for 26 years and published 80 scientific papers in reputed journals both in Thai and English. He is the CEO of Asian Phytoceuticals Public Company Limited and the Principal Investigator of Operation BIM Research Team consisting of Assoc Prof Dr Ampai Panthong, Prof Dr Souwalak Phongpaichit, Assoc Prof Dr Wilawan Mahabussarakam and Assoc Prof Dr Siriwan Ong-chai.

E-mail: pwapco@gmail.com